Putative Pharmacological Depression and Anxiety-Related Targets of Calcitriol Explored by Network Pharmacology and Molecular Docking

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Jul 27

PMID 39065743

Authors

Bruna R Kouba

Glorister A Alte

Ana Lucia S Rodrigues

Affiliations

Soon will be listed here.

Abstract

Depression and anxiety disorders, prevalent neuropsychiatric conditions that frequently coexist, limit psychosocial functioning and, consequently, the individual's quality of life. Since the pharmacological treatment of these disorders has several limitations, the search for effective and secure antidepressant and anxiolytic compounds is welcome. Vitamin D has been shown to exhibit neuroprotective, antidepressant, and anxiolytic properties. Therefore, this study aimed to explore new molecular targets of calcitriol, the active form of vitamin D, through integrated bioinformatic analysis. Calcitriol targets were predicted in SwissTargetPrediction server (2019 version). The disease targets were collected by the GeneCards database searching the keywords "depression" and "anxiety". Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to analyze the intersections of targets. Network analyses were carried out using GeneMania server (2023 version) and Cytoscape (V. 3.9.1.) software. Molecular docking predicted the main targets of the network and Ligplot predicted the main intermolecular interactions. Our study showed that calcitriol may interact with multiple targets. The main targets found are the vitamin D receptor (VDR), histamine H3 receptor (H3R), endocannabinoid receptors 1 and 2 (CB1 and CB2), nuclear receptor NR1H3, patched-1 (PTCH1) protein, opioid receptor NOP, and phosphodiesterase enzymes PDE3A and PDE5A. Considering the role of these targets in the pathophysiology of depression and anxiety, our findings suggest novel putative mechanisms of action of vitamin D as well as new promising molecular targets whose role in these disorders deserves further investigation.

References

Howlett A . The CB1 cannabinoid receptor in the brain. Neurobiol Dis. 1999; 5(6 Pt B):405-16. DOI: 10.1006/nbdi.1998.0215. View

Gavioli E, Marzola G, Guerrini R, Bertorelli R, Zucchini S, de Lima T . Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci. 2003; 17(9):1987-90. DOI: 10.1046/j.1460-9568.2003.02603.x. View

Zhou D, Li Y, Tian T, Quan W, Wang L, Shao Q . Role of the endocannabinoid system in the formation and development of depression. Pharmazie. 2018; 72(8):435-439. DOI: 10.1691/ph.2017.7474. View

Deng C, Liu Q, Zhao H, Qian L, Lei W, Yang W . Activation of NR1H3 attenuates the severity of septic myocardial injury by inhibiting NLRP3 inflammasome. Bioeng Transl Med. 2023; 8(3):e10517. PMC: 10189481. DOI: 10.1002/btm2.10517. View

Kouba B, Torra A, Camargo A, Rodrigues A . The antidepressant-like effect elicited by vitamin D is associated with BDNF/TrkB-related synaptic protein synthesis. Metab Brain Dis. 2022; 38(2):601-611. DOI: 10.1007/s11011-022-01115-0. View

Guo Y, He L, Zhang M, Wang F, Liu F, Peng W . 1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Aβ1-40 brain-to-blood efflux and peripheral uptake transport. Neuroscience. 2016; 322:28-38. DOI: 10.1016/j.neuroscience.2016.01.041. View

Malhi G, Mann J . Depression. Lancet. 2018; 392(10161):2299-2312. DOI: 10.1016/S0140-6736(18)31948-2. View

Vitale G, Filaferro M, Micioni Di Bonaventura M, Ruggieri V, Cifani C, Guerrini R . Effects of [Nphe, Arg, Lys] N/OFQ-NH (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. J Psychopharmacol. 2017; 31(6):691-703. DOI: 10.1177/0269881117691456. View

Venkatachalam K, Zhong S, Dubiel M, Satala G, Sadek B, Stark H . The Novel Pimavanserin Derivative ST-2300 with Histamine H Receptor Affinity Shows Reduced 5-HT Binding, but Maintains Antidepressant- and Anxiolytic-like Properties in Mice. Biomolecules. 2022; 12(5). PMC: 9138994. DOI: 10.3390/biom12050683. View

10.

Mechoulam R, Parker L . The endocannabinoid system and the brain. Annu Rev Psychol. 2012; 64:21-47. DOI: 10.1146/annurev-psych-113011-143739. View

11.

Vieira G, Cavalli J, Goncalves E, Braga S, Ferreira R, Santos A . Antidepressant-Like Effect of Terpineol in an Inflammatory Model of Depression: Involvement of the Cannabinoid System and D2 Dopamine Receptor. Biomolecules. 2020; 10(5). PMC: 7280984. DOI: 10.3390/biom10050792. View

12.

Sheng J, Zhang S, Wu L, Kumar G, Liao Y, Gk P . Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease. Front Aging Neurosci. 2022; 14:1019187. PMC: 9577554. DOI: 10.3389/fnagi.2022.1019187. View

13.

Gobira P, LaMar J, Marques J, Sartim A, Silveira K, Santos L . CB1 Receptor Silencing Attenuates Ketamine-Induced Hyperlocomotion Without Compromising Its Antidepressant-Like Effects. Cannabis Cannabinoid Res. 2022; 8(5):768-778. PMC: 10771879. DOI: 10.1089/can.2022.0072. View

14.

Li J, Wang H, Liu D, Li X, He L, Pan J . CB2R activation ameliorates late adolescent chronic alcohol exposure-induced anxiety-like behaviors during withdrawal by preventing morphological changes and suppressing NLRP3 inflammasome activation in prefrontal cortex microglia in mice. Brain Behav Immun. 2023; 110:60-79. DOI: 10.1016/j.bbi.2023.02.001. View

15.

Peng Z, Deng B, Jia J, Hou W, Hu S, Deng J . Liver X receptor β in the hippocampus: A potential novel target for the treatment of major depressive disorder?. Neuropharmacology. 2018; 135:514-528. DOI: 10.1016/j.neuropharm.2018.04.014. View

16.

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S . PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2020; 49(D1):D1388-D1395. PMC: 7778930. DOI: 10.1093/nar/gkaa971. View

17.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

18.

Zhu P, Tang J, Liang X, Luo Y, Wang J, Li Y . Activation of liver X receptors protects oligodendrocytes in CA3 of stress-induced mice. Front Pharmacol. 2022; 13:936045. PMC: 9358133. DOI: 10.3389/fphar.2022.936045. View

19.

Melas P, Scherma M, Fratta W, Cifani C, Fadda P . Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. Int J Mol Sci. 2021; 22(4). PMC: 7917759. DOI: 10.3390/ijms22041863. View

20.

Ubaldi M, Cannella N, Borruto A, Petrella M, Micioni Di Bonaventura M, Soverchia L . Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders. Int J Mol Sci. 2021; 22(23). PMC: 8657682. DOI: 10.3390/ijms222312956. View